awmsg logo



daptomycin (Cubicin®)


Reference No. 3721

Publication date:
17/05/2018


Appraisal information

daptomycin (Cubicin®) 350 mg powder for solution for injection/infusion
daptomycin (Cubicin®) 500 mg powder for solution for injection/infusion


Company: Merck Sharp & Dohme Ltd
BNF category: Infections
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 20/04/2018

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, daptomycin (Cubicin®) cannot be endorsed for use within NHS Wales for the treatment of paediatric (1 to 17 years of age) patients with Staphylococcus aureus bacteraemia associated with cSSTI.
Statement of Advice (SOA)
Download